Bausch Health Cos., Inc. (BHC)
8.56
-0.17
(-1.95%)
USD |
NYSE |
Nov 19, 16:00
8.565
0.00 (0.00%)
Pre-Market: 20:00
Bausch Health Cos. Enterprise Value : 22.42B for Nov. 19, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 19, 2026 | 22.42B |
| November 18, 2026 | 22.48B |
| November 17, 2026 | 22.38B |
| November 16, 2026 | 22.37B |
| November 13, 2026 | 22.34B |
| November 12, 2026 | 22.30B |
| November 11, 2026 | 22.34B |
| November 10, 2026 | 22.32B |
| November 09, 2026 | 22.36B |
| November 06, 2026 | 22.28B |
| November 05, 2026 | 22.19B |
| November 04, 2026 | 22.34B |
| November 03, 2026 | 22.26B |
| November 02, 2026 | 22.22B |
| October 30, 2026 | 22.28B |
| October 29, 2026 | 22.55B |
| October 28, 2026 | 21.80B |
| October 27, 2026 | 21.58B |
| October 26, 2026 | 21.59B |
| October 23, 2026 | 21.62B |
| October 22, 2026 | 21.64B |
| October 21, 2026 | 21.63B |
| October 20, 2026 | 21.62B |
| October 19, 2026 | 21.58B |
| October 16, 2026 | 21.57B |
| Date | Value |
|---|---|
| October 15, 2026 | 21.58B |
| October 14, 2026 | 21.42B |
| October 13, 2026 | 21.42B |
| October 12, 2026 | 21.43B |
| October 09, 2026 | 21.47B |
| October 08, 2026 | 21.47B |
| October 07, 2026 | 21.52B |
| October 06, 2026 | 21.47B |
| October 05, 2026 | 21.42B |
| October 02, 2026 | 21.38B |
| October 01, 2026 | 21.36B |
| September 30, 2026 | 21.40B |
| September 29, 2026 | 22.08B |
| September 28, 2026 | 22.07B |
| September 25, 2026 | 22.04B |
| September 24, 2026 | 22.02B |
| September 23, 2026 | 22.04B |
| September 22, 2026 | 22.08B |
| September 21, 2026 | 22.02B |
| September 18, 2026 | 22.03B |
| September 17, 2026 | 22.02B |
| September 16, 2026 | 22.04B |
| September 15, 2026 | 22.03B |
| September 14, 2026 | 22.12B |
| September 11, 2026 | 22.10B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NervGen Pharma Corp. | 150.19M |
| Milestone Pharmaceuticals, Inc. | 48.12M |
| Appili Therapeutics, Inc. | 9.454M |
| Clearmind Medicine, Inc. | -13.32M |
| Lexaria Bioscience Corp. | 3.495M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 446.00M |
| Revenue (Quarterly) | 2.941B |
| Total Expenses (Quarterly) | 2.505B |
| EPS Diluted (Quarterly) | 1.145 |
| Gross Profit Margin (Quarterly) | 67.29% |
| Profit Margin (Quarterly) | 15.16% |
| Earnings Yield | -26.77% |
| Operating Earnings Yield | 93.92% |
| Normalized Earnings Yield | 12.48 |